Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Linearity Study Using UV – V 2.0

Posted on By

Analytical Method Development: Linearity Study Using UV – V 2.0

SOP for Conducting Linearity Studies in UV Spectrophotometric Method Development


Department Analytical Method Development
SOP No. SOP/AMD/093/2025
Supersedes SOP/AMD/093/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the procedure for performing linearity studies for UV spectrophotometric methods during analytical method development. It ensures that the method provides accurate and proportional response over a defined

concentration range in accordance with ICH Q2(R1).

2. Scope

This SOP applies to the Analytical Method Development (AMD) department and covers linearity studies performed for Active Pharmaceutical Ingredients (APIs) and drug products analyzed by UV-visible spectrophotometry.

3. Responsibilities

  • Analytical Chemist: Prepares dilution series, measures absorbance, and performs calculations.
  • Reviewer: Verifies calibration curve, linear regression output, and correlation coefficient.
  • QA Officer: Audits raw data and ensures compliance with validation protocols.
  • Head – AMD: Approves final linearity data for method validation or regulatory submission.

See also  Analytical Method Development: SOP for Verification of Analytical Procedures - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that linearity studies are performed according to validated procedures and meet required statistical acceptance criteria.

5. Procedure

5.1 Preparation of Standard Stock Solution

  1. Accurately weigh approximately 100 mg of the API.
  2. Dissolve in a suitable solvent (e.g., water, methanol, ethanol) in a 100 mL volumetric flask.
  3. Sonicate to dissolve completely and make up to volume. This yields a stock solution of 1 mg/mL (1000 µg/mL).
  4. Label as Standard Stock Solution and document in Annexure-1: Preparation Log.

5.2 Preparation of Linearity Dilutions

  1. From the stock solution, prepare at least five concentration levels (e.g., 50%, 75%, 100%, 125%, and 150% of test concentration).
  2. Example for 100 µg/mL target concentration:
    • 50 µg/mL
    • 75 µg/mL
    • 100 µg/mL
    • 125 µg/mL
    • 150 µg/mL
  3. Use the same diluent for all dilutions and store samples in amber glassware if photosensitive.
  4. Log each dilution in Annexure-2: Linearity Dilution Table.

5.3 Measurement of Absorbance

  1. Use UV-visible spectrophotometer calibrated and qualified as per instrument SOP.
  2. Measure absorbance of each dilution in triplicate at the selected λmax.
  3. Use 1.0 cm matched quartz cuvettes and ensure instrument is zeroed using blank solvent.
  4. Document readings in Annexure-3: Absorbance Data Sheet.
See also  Analytical Method Development: SOP for Investigation of Method Transfer Failures - V 2.0

5.4 Plotting Calibration Curve

  1. Plot absorbance values on the Y-axis and concentration on the X-axis.
  2. Use Microsoft Excel or validated software to perform linear regression.
  3. Obtain slope, intercept, correlation coefficient (r), and regression equation.
  4. Example output: y = 0.0047x + 0.0032; R² = 0.9996
  5. Paste graph and calculations into Annexure-4: Calibration Graph and Regression Output.

5.5 Evaluation Criteria

  1. Acceptance Criteria:
    • Correlation coefficient (r) ≥ 0.995
    • Line passes through or near origin (intercept ≤ ±0.01)
    • Residuals randomly distributed (no systematic error)
  2. Calculate %RSD at each concentration level. Acceptance limit: ≤2.0%
  3. Document in Annexure-5: Linearity Summary Sheet.

5.6 Repeatability Check

  1. Inject 100% concentration level six times.
  2. Calculate %RSD of absorbance values. Acceptance limit: ≤2.0%
  3. Include in final method validation report.

6. Abbreviations

  • UV: Ultraviolet
  • API: Active Pharmaceutical Ingredient
  • RSD: Relative Standard Deviation
  • SOP: Standard Operating Procedure
  • r: Correlation Coefficient
  • λmax: Wavelength of Maximum Absorbance

7. Documents

  1. Preparation Log – Annexure-1
  2. Linearity Dilution Table – Annexure-2
  3. Absorbance Data Sheet – Annexure-3
  4. Calibration Graph and Regression Output – Annexure-4
  5. Linearity Summary Sheet – Annexure-5
See also  Analytical Method Development: Method Optimization Protocol - V 2.0

8. References

  • ICH Q2(R1) – Validation of Analytical Procedures: Text and Methodology
  • USP <857> – Ultraviolet-Visible Spectroscopy
  • Pharmaceutical Method Validation Guidelines – FDA, EMA

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Preparation Log

Compound Weight (mg) Solvent Volume (mL) Prepared By
API-LIN-001 100.0 Methanol 100 Rajesh Kumar

Annexure-2: Linearity Dilution Table

Level (%) Concentration (µg/mL) Dilution Details
50% 50 5 mL stock in 100 mL
100% 100 10 mL stock in 100 mL

Annexure-3: Absorbance Data Sheet

Concentration (µg/mL) Absorbance 1 Absorbance 2 Absorbance 3 Mean
50 0.238 0.240 0.239 0.239

Annexure-4: Calibration Graph and Regression Output

Attach printed graph and Excel regression table showing slope, intercept, and R².

Annexure-5: Linearity Summary Sheet

Parameter Value Acceptance Status
Correlation Coefficient (R²) 0.9996 ≥ 0.995 Pass
%RSD (100%) 1.2% ≤ 2.0% Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Updated acceptance criteria and added regression plot section Annual SOP Review
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: API Manufacturing: SOP for Qualification of New Analytical Equipment – V 2.0
Next Post: Elixir Department: SOP for Sampling from Storage Tank – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version